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Neurodegeneration with brain iron accumulation encompasses a heterogeneous group of rare neurodegenerative disorders that
are characterized by iron accumulation in the brain. Severe generalized dystonia is frequently a prominent symptom and can be
very disabling, causing gait impairment, difﬁculty with speech and swallowing, pain and respiratory distress. Several case
reports and one case series have been published concerning therapeutic outcome of pallidal deep brain stimulation in dystonia
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there may be a reporting bias towards favourable outcome. Thus, we undertook this multi-centre retrospective study to gather
worldwide experiences with bilateral pallidal deep brain stimulation in patients with neurodegeneration with brain iron accu-
mulation. A total of 16 centres contributed 23 patients with conﬁrmed neurodegeneration with brain iron accumulation and
bilateral pallidal deep brain stimulation. Patient details including gender, age at onset, age at operation, genetic status, mag-
netic resonance imaging status, history and clinical ﬁndings were requested. Data on severity of dystonia (Burke Fahn Marsden
Dystonia Rating Scale—Motor Scale, Barry Albright Dystonia Scale), disability (Burke Fahn Marsden Dystonia Rating Scale—
Disability Scale), quality of life (subjective global rating from 1 to 10 obtained retrospectively from patient and caregiver) as well
as data on supportive therapy, concurrent pharmacotherapy, stimulation settings, adverse events and side effects were collected.
Data were collected once preoperatively and at 2–6 and 9–15 months postoperatively. The primary outcome measure
was change in severity of dystonia. The mean improvement in severity of dystonia was 28.5% at 2–6 months and 25.7% at
9–15 months. At 9–15 months postoperatively, 66.7% of patients showed an improvement of 20% or more in severity of
dystonia, and 31.3% showed an improvement of 20% or more in disability. Global quality of life ratings showed a median
improvement of 83.3% at 9–15 months. Severity of dystonia preoperatively and disease duration predicted improvement in
severity of dystonia at 2–6 months; this failed to reach signiﬁcance at 9–15 months. The study conﬁrms that dystonia in
neurodegeneration with brain iron accumulation improves with bilateral pallidal deep brain stimulation, although this improve-
ment is not as great as the beneﬁt reported in patients with primary generalized dystonias or some other secondary dystonias.
The patients with more severe dystonia seem to beneﬁt more. A well-controlled, multi-centre prospective study is necessary to
enable evidence-based therapeutic decisions and better predict therapeutic outcomes.
Keywords: Neurodegeneration with brain iron accumulation; dystonia; deep brain stimulation; globus pallidus
Abbreviations: BFMDRS=Burke Fahn Marsden Dystonia Rating Scale; GPi-DBS=bilateral pallidal deep brain stimulation;
NBIA=neurodegeneration with brain iron accumulation
Introduction
Neurodegeneration with brain iron accumulation (NBIA) encom-
passes a heterogeneous group of rare progressive disorders which
are characterized by iron accumulation in the brain (Hayﬂick et al.,
2003). Diagnosis is usually made according to the following crite-
ria: (i) progressive disorder; with (ii) at least one of the following
symptoms: dystonia, rigidity, tremor, bradykinesia or choreoathe-
tosis; and (iii) an abnormal MRI with hypointensity of the pallidum
on the T2-weighted images (Swaiman, 2001).
Several genetic subtypes of NBIA are currently emerging. The
most common subtype, pantothenate kinase-associated neurode-
generation, is caused by mutations in the PANK2 gene (Zhou
et al., 2001) and accounts for 50% of cases of NBIA (Hayﬂick
et al., 2003). Further genetic defects associated with NBIA are
mutations in the PLA2G6 gene (Morgan et al., 2006), and disor-
ders of iron metabolism, such as aceruloplasminaemia (Harris,
1995) and neuroferritinopathy (Curtis et al., 2001). Patients exhi-
biting symptoms typical of NBIA without any of these known
mutations are classiﬁed as ‘idiopathic NBIA’ and their disease is
probably caused by, as yet unknown, other genes (Gregory et al.,
2009).
The clinical presentation, the age of onset and the progression
rate of NBIA are highly variable, even amongst siblings with iden-
tical underlying mutations, and there is a considerable degree of
phenotypic heterogeneity even in cases with PANK2 mutation-
positive status (Thomas et al., 2004). Severe generalized dystonia
is frequently a prominent clinical symptom of NBIA, which can be
very disabling and cause gait impairment, difﬁculty with speech
and swallowing, pain, respiratory distress and, in some cases,
death due to dystonic storm, respiratory failure or infection. Due
to small patient numbers, pharmacotherapy of dystonia in NBIA is
not evidence-based, and thus guided by therapeutic experiences in
other forms of dystonia. Patients are often treated with anticholi-
nergics, such as trihexiphenidyl or gamma-aminobutyric acid ago-
nists such as benzodiazepines or baclofen, orally or intrathecally
(Albright et al., 1996). There are some reports of botulinum toxin
being effective (Dressler et al., 2001) for particularly bothersome
focal symptoms, and many patients receive regular botulinum
toxin injections. Levodopa has been reported to have a positive
effect on some of the disabling movements seen in NBIA patients
without PANK2 mutations (Gregory and Hayﬂick 2005; Clement
et al., 2007). However, in most cases with severe dystonia, phar-
macological therapy, including botulinum toxin injections, is unsa-
tisfactory. The limited beneﬁts of medical treatments have
prompted early attempts with neurosurgical therapy.
Several cases have been published in which there has been
improvement in dystonia associated with NBIA after bilateral tha-
lamotomy (Tsukamoto et al., 1992) as well as unilateral (Justesen
et al., 1999) or bilateral pallidotomy (Kyriagis et al., 2004; Balas
et al., 2006). However, since stereotactic lesioning is an irrevers-
ible procedure, its use in children and adolescents raises several
concerns (especially for bilateral procedures, which have higher
risk of severe side effects). With the advent of deep brain stimu-
lation (DBS) as an effective and reversible therapeutic measure to
treat dystonia, the number of stereotactic lesioning procedures has
dropped considerably. The DBS target of choice in dystonia is
presently the globus pallidus internus (GPi). Safety and efﬁcacy
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primary dystonia has been documented in two prospective
double-blind trials with either primary generalized or primary
segmental dystonia (Vidailhet et al., 2005; Kupsch et al., 2006).
For secondary dystonias, data are more limited and therapeutic
outcomes are mixed. Good results have so far been obtained
in patients with tardive dystonias (Trottenberg et al., 2005; Sako
et al., 2008). In other forms of secondary dystonias, such as
dystonia-plus syndromes, post-traumatic, post-anoxic, post-ence-
phalitic or cerebral palsy associated dystonia, small cohorts and
single cases have been reported and the results are
variable (Loher et al., 2000; Zorzi et al., 2005; Vidailhet et al.,
2009).
To date, several case reports (Umemura et al., 2004; Sharma
et al., 2005; Krause et al., 2006; Shields et al., 2007; Mikati et al.,
2009) and one series of six patients (Castelnau et al., 2005) have
been published concerning therapeutic outcome of bilateral
GPi-DBS in NBIA-dystonia. Four of the ﬁve cases report a favour-
able outcome. However, with case studies, there may be a report-
ing bias towards favourable outcome. Furthermore, factors
predicting a favourable outcome of DBS cannot be estimated
from small series.
Thus, we initiated a multi-centre retrospective study with the
objective of gathering worldwide experiences with bilateral
GPi-DBS in patients with NBIA. Our goal was to provide a wide
and unselected coverage of NBIA patients operated on so far by
contacting movement disorders centres, surgical centres and
patient support groups worldwide. We hypothesized that
GPi-DBS in patients with NBIA reduces dystonia as assessed by
the Burke Fahn Marsden Dystonia Rating Scale (BFMDRS), but
is overall less effective than reported in single cases and small
series published thus far.
Materials and methods
A total of 16 international centres were involved in this retrospective
study. The centres are listed in Appendix A.
Recruitment
DBS and movement disorders centres around the world were con-
tacted and asked to contribute patients with NBIA who were treated
with GPi-DBS. We received a contact list of all centres worldwide
known to implant DBS devices by the only manufacturer at the time
(Medtronic Inc.). All of these were contacted a minimum of two times,
either via email or phone. A similar recruitment approach has been
used previously in retrospective multi-centre studies (Voon et al.,
2008). In parallel, contacts with patients and families were established
through patient organizations, most notably ‘Hoffnungsbaum e. V.’,
the German NBIA Association, as well as the NBIA Disorders
Association, which is the patient organization in the United States.
Additionally, two of the patients were extracted from previous publi-
cations, either entirely (Umemura et al., 2004) or partially (Krause
et al., 2006). Centres were asked to contribute every patient regard-
less of outcome.
Inclusion criteria
Inclusion criteria were: (i) conﬁrmed NBIA (as assessed by a specialized
centre); (ii) presence of moderate to severe dystonia; and (iii) implan-
tation of bilateral GPi-DBS to treat dystonia. Diagnostic criteria for
NBIA used here were: (i) progressive disorder; with (ii) at least one
of the following features: dystonia, rigidity, tremor, bradykinesia, chor-
eoathetosis; and (iii) the presence of abnormal MRI with hyperintensity
of the pallidum on T1 images and hypointensity on T2 images
(Swaiman, 2001).
Protocol
All centres able to contribute data or cases were sent a standardized
data sheet. First, patient details including gender, age at onset, age at
diagnosis, age at operation, genetic status, MRI status, history and
clinical ﬁndings were requested. Secondly, data on severity of dystonia
were collected, including (if available) the BFMDRS motor (BFMDRS-
M) and disability (BFMDRS-D) scores (Burke et al., 1985) and the
Barry Albright Dystonia Scale (Barry et al., 1999). Thirdly, data on
quality of life were requested in the form of a retrospective subjective
global rating (from 1 to 10; 0 equalling no quality of life, 10 equivalent
to maximal quality of life) by patient and caregiver. Finally, data on
supportive therapy, concurrent pharmacotherapy, stimulation settings,
adverse events and side effects were also requested. Measures of
severity of dystonia, quality of life, stimulation settings and concurrent
pharmacotherapy were collected preoperatively, at 2–6 months post-
operatively, as well as at 9–15 months postoperatively. A summary of
all data collected during the study can be found in Table 1.
Outcome measures
Change in severity of dystonia as measured by the BFMDRS-M (Burke
et al., 1985) was chosen as the primary outcome measure. The clin-
ically relevant difference for BFMDRS-M was set at 20% or more, in
analogy to previous studies of secondary dystonia (Vidailhet et al.,
2009). To conﬁrm the ﬁndings of the BFMDRS-M in this
Table 1 Parameters collected during the study
Study protocol
Preoperative assessment
Patient history (age at operation, age at onset,
disease duration, date of birth, gender)
Neurological examination
Brain MRI status
Genetic testing (if available)
Burke Fahn Marsden Dystonia Rating Scale
(severity of dystonia and disability)
Barry Albright Dystonia Scale (severity of dystonia)
Subjective quality of life rating (patient and caregiver)
Medication, supportive therapy
Assessment at 2–6 and 9–15 months postoperatively
Burke Fahn Marsden Dystonia Rating Scale
(severity of dystonia and disability)
Barry Albright Dystonia Scale (severity of dystonia)
Subjective quality of life rating (patient and caregiver)
Stimulation settings, target point
Medication, supportive therapy
Adverse events, side effects
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Barry Albright Dystonia Scale (Barry et al., 1999), which is particularly
suited for paediatric dystonia. Secondary outcome measures were
(i) disability (as assessed using the BFMDRS-D); and (ii) quality of
life as assessed using a global rating of quality of life by caregiver.
An improvement of 20% or more in the BFMDRS-D was considered
clinically relevant, as was a 20% improvement in global quality of life
ratings.
Data analysis
One patient was excluded from the analysis because the stimulation
electrodes were not located in the GPi. Normality of data distribution
was tested using a Kolmogorov–Smirnov Test. All data were normally
distributed. Percentages of patients who attained the clinically relevant
difference were calculated. Then, t-tests for dependent samples were
performed comparing values obtained for preoperative severity of dys-
tonia, disability and quality of life to values obtained at 2–6 months
as well as at 9–15 months postoperatively. To account for cases in
which data were missing, analysis was performed for each variable
(e.g. BFMDRS-M) using only those cases for which values were avail-
able at all three time points. Thus, different cases may be included for
different parameters. For the secondary outcome measures, we per-
formed a Bonferroni correction to account for multiple t-tests. We also
performed a linear regression to determine if we could identify, pre-
operatively, factors that were predictive of improvement in severity of
dystonia and other measures of therapeutic outcome. Because several
linear regressions were calculated, a Bonferroni correction was applied
to adjust the level of signiﬁcance accordingly. Data analysis was per-
formed using Statistical Package for the Social Sciences 17.0.
The study was conducted with approval of the local Ethics
Committee of the University Hospital of Cologne, and was carried
out according to the Guidelines of the Declaration of Helsinki.
Informed written consent was obtained either from patients or, in
the case of patients who were either unable to give their written
consent or were minors, from their legal representatives. All data
were then entered into a database in an anonymous format according
to the data protection laws in Germany.
Results
In total, 23 patients were included in the data analysis. Four of
these have already been published elsewhere (Kurlemann et al.,
1991; Umemura et al., 2004; Krause et al., 2006; Shields et al.,
2007). Patient details can be found in Table 2; preoperative mean
descriptive group statistics are given in Table 3.
Primary outcome measure
Severity of dystonia
BFMDRS-M at all three time points were available for 14 patients.
The severity of dystonia, as assessed by the BFMDRS-M, improved
signiﬁcantly after GPi-DBS both at 2–6 months (T=3.6, P50.01)
and at 9–15 months postoperatively (T=2.7, P50.05) com-
pared to before surgery (Fig. 1A). The mean improvement in
severity of dystonia was 28.5% at 2–6 months and 25.7% at
9-15 months. Of 19 patients for whom a BFMDRS-M was avail-
able at 2–6 months, 11 (57.9%) showed an improvement of 20%
or more. At 9–15 months, 10 of 15 patients (66.7%) showed an
improvement of 20% or more on the BFMDRS-M (see also pie
chart in Fig. 2A; for analysis based on absolute values, see
Supplementary Fig. S1). A line diagram of individual patients’ out-
comes is shown in Fig. 1D and G: of 11 patients who had a
clinically relevant improvement at 2–6 months, 8 (72.7%) main-
tained an improvement of 20% or more, one declined, and no
information was available on the remaining two. Of the eight
patients who did not improve at 2–6 months, two (25%)
improved more than 20% at 9–15 months, two (25%) remained
the same and one (12.5%) worsened. No information was avail-
able on the other three patients at 9–15 months.
The results obtained from the Barry Albright Dystonia Scale
showed comparable results (n=14) with a signiﬁcant improvement
in severity of dystonia both at 2–6 months (T=4.3, P50.001) as
well as at 9–15 months (T=3.2, P50.01).
Secondary outcome measures
Two secondary outcome measures were investigated, namely the
BFMDRS disability scale and the global quality of life ratings by
the caregivers. Thus, using an initial signiﬁcance level of P=0.05,
after Bonferroni correction (two measures, two paired t-tests
each), the adjusted signiﬁcance level applied was P=0.01.
Disability
BFMDRS-D at all three time points were available for 15 patients.
For these 15, BFMDRS-D was not signiﬁcantly improved at either
2–6 months postoperatively (T=2.5), or at 9–15 months post-
operatively (T=1.6, Fig. 1B). Out of 20 patients for whom a
BFMDRS-D was available at 2–6 months, 7 (35.0%) showed an
improvement of more than 20%. Out of the 16 patients for
whom a BFMDRS-D was available at 9–15 months, 5 (31.3%)
showed an improvement of 20% or more (for a pie chart of
these results, see Fig. 2B). However, the mean improvement for
the entire group at 2–6 months was only 15.8% and decreased
further at 9–15 months to 9.7%. A line diagram of individual
patients’ outcomes is shown in Figs 1E and H.
Quality of life
The subjective global ratings obtained retrospectively from both
patients and caregivers were used. Caregiver ratings were avail-
able for all three time points in 17 patients, whereas all patient
ratings were only available for 14 patients. Since some of the
patients probably had cognitive deﬁcits and assessment of quality
of life in children using abstract numbers is of limited validity, we
decided to use only caregiver ratings as a secondary outcome
measure. There was a signiﬁcant improvement in quality of life
as rated by the caregiver both at 2–6 months (T=4.3, P50.001),
and at 9–15 months (T=3.1, P50.01). These results are shown
alongside the patient ratings in Fig. 1C. There was an 80.4%
median improvement in quality of life at three months and an
83.3% median improvement at 9–15 months. At 2–6 months,
14 (70.0%) out of 20 caregivers rated an improvement in quality
of life of 20% or more. At 9–15 months, 11 (64.7%) out of 17
caregivers rated an improvement in quality of life for the patient
of 20% or more. A pie chart of these results is shown in Fig. 2C.
A line diagram of individual patients’ outcomes is shown in Fig. 1F
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between 2–6 months and 9–15 months.
Prediction of therapeutic outcome
Given the wide range of outcomes in severity of dystonia, we
atempted to identify predictors of outcome. We found that the
preoperative severity of dystonia, as assessed by the BFMDRS-M,
predicts improvement in dystonia at 2–6 months and at 9–15
months post-surgery (linear regression, corr. r
2=0.31, F=9.4,
P50.01, Fig. 3A; linear regression, corr. r
2=0.29, F=7.3,
P50.05, respectively). Thus, patients with more severe dystonia
improved more. However, the ﬁnding at 9–15 months was not
signiﬁcant at the Bonferroni-corrected signiﬁcance level of
Table 2 Patient characteristics
Patient
number
Age at
onset of
symptoms
(years)
Age at time
of diagnosis
(years)
Age at
operation
(years)
Duration of
disease
(years)
Gender Genetics MRI
1 1 5 6 5 Female PKAN Eye of the tiger
2 1 6 9 8 Male PKAN Eye of the tiger
3 2 11 16 14 Male PKAN Eye of the tiger
4 2 5 12 10 Female Not tested Eye of the tiger
5 2 5 6 4 Female PKAN Eye of the tiger
6 2 5 9 7 Female Not tested Eye of the tiger
7 3 5 12 9 Male Not tested Eye of the tiger
8 4 8 14 10 Male PKAN Eye of the tiger
9
a 6 10 13 7 Male PKAN Eye of the tiger
10
b 8 10 17 9 Male PKAN Eye of the tiger
11
c 8 36 36 28 Male Not tested Eye of the tiger
12 9 11 13 4 Male PKAN Eye of the tiger
13 9 11 16 7 Female PKAN Eye of the tiger
14 9 13 17 8 Male PKAN Eye of the tiger
15 10 13 17 7 Male Not tested Eye of the tiger
16
d 11 13 29 18 Female Non-PKAN Eye of the tiger
17 12 16 32 20 Female PKAN Eye of the tiger
18 12 12 15 3 Male PKAN Eye of the tiger
19 12 13 24 12 Female PKAN Eye of the tiger
20 14 16 20 6 Female Not tested Eye of the tiger
21 14 33 36 22 Male PKAN Eye of the tiger
22 14 19 27 13 Male Not tested Eye of the tiger
23 15 15 19 4 Male Not tested Eye of the tiger
MeanSD 7.84.8 12.78.0 18.08.8 10.26.4 10 females
(43.5 %)
13 males
(56.5 %)
60.9% PKAN
4.3 % non-PKAN
34.8 % not tested
PKAN = pantothenate kinase-associated neurodegeneration.
a Partially cited from Krause et al. (2006).
b Referred to in Shields et al. (2007).
c Cited from Umemura et al. (2004).
d Partially cited from Kurlemann et al. (1991).
Table 3 Mean characteristics of group preoperatively
n MeanSD Range
Age at onset (years) 23 7.84.8 1.0–15.0
Age at diagnosis (years) 23 12.78.0 5.0–36.0
Age at operation (years) 23 18.08.8 6.0–36.0
Disease duration (years) 23 10.26.4 3.0–28.0
BFMDRS-M (out of 120) 21 71.226.0 21.0–112.0
BFMDRS-D (out of 30) 22 21.05.8 9.0–30.0
Barry Albright Dystonia Scale (out of 32) 21 21.06.3 6.0–30.0
Global quality of life—patient (out of 10) 16 3.72.8 0–9.0
Global quality of life—caregiver (out of 10) 21 3.02.5 0–9.0
Care and Comfort Hypertonicity Questionnaire (out of 189) 17 104.141.8 31.0–177.0
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age improvements, the correlation is no longer signiﬁcant,
although there is a trend for signiﬁcance (P=0.051 and
P=0.087, respectively). The improvement in severity of dystonia
at 2–6 months is better predicted by duration of disease and
severity of dystonia preoperatively (linear regression, corr.
r
2=0.41, F=14.1, P50.001, Fig. 3B). Thus, patients with more
severe dystonia and longer (and thus possibly slower) disease
duration improved signiﬁcantly more. However, both parameters
co-vary to a certain extent (longer disease duration frequently
means more dystonia).
Improvement in disability at three months could be predicted by
the improvement in severity of dystonia (linear regression, corr.
r
2=0.40, F=13.2, P50.005, Fig. 3C). Likewise, improvement in
disability at 9–15 months could be predicted by the improvement
in severity of dystonia at 9–15 months (linear regression, corr.
r
2=0.50, F=15.0, P50.005). However, factors available
preoperatively such as extent of disability, severity of dystonia or
other factors did not predict postoperative improvement in
disability.
Genetic status: subanalysis inpatients
with pantothenate kinase-associated
neurodegeneration
Genetic testing was performed in 15 patients. Fourteen of these
had a PANK2 gene mutation. In nine PANK2 mutation-positive
patients in whom BFMDRS-M were available both at 2–6 and at
9–15 months, there was a signiﬁcant improvement at 2–6 months
(T=2.9, P50.05), but not at 9–15 months (T=1.3). Improvement
in BFMDRS-M at 2–6 months was 27.2%, matching the outcome
in the entire cohort.
120
100
60
40
20
20
10
10
80
0
120
100
60
40
20
80
0
0
S
e
v
e
r
i
t
y
 
o
f
 
d
y
s
t
o
n
i
a
S
e
v
e
r
i
t
y
 
o
f
 
d
y
s
t
o
n
i
a
%
 
c
h
a
n
g
e
 
i
n
 
s
e
v
e
r
i
t
y
 
o
f
 
d
y
s
t
o
n
i
a
S
e
v
e
r
i
t
y
 
o
f
 
d
i
s
a
b
i
l
i
t
y
Severity of dystonia
(BFMDRS-M)
Severity of disability
(BFMDRS-D)
*
(*
)
* **
* *** * **
PREOP 2-6 
MONTHS
POSTOP
9-15 
MONTHS
POSTOP
2-6 
MONTHS
POSTOP
9-15 
MONTHS
POSTOP
PREOP 2-6 
MONTHS
POSTOP
9-15 
MONTHS
POSTOP
PREOP 2-6 
MONTHS
POSTOP
9-15 
MONTHS
POSTOP
PREOP 2-6 
MONTHS
POSTOP
9-15 
MONTHS
POSTOP
PREOP 2-6 
MONTHS
POSTOP
9-15 
MONTHS
POSTOP
PREOP PREOP 2-6 
MONTHS
POSTOP
9-15 MONTHS
POSTOP
30
20
15
25
10
0
5
S
e
v
e
r
i
t
y
 
o
f
 
d
i
s
a
b
i
l
i
t
y
%
 
c
h
a
n
g
e
 
i
n
 
d
i
s
a
b
i
l
i
t
y
2-6 
MONTHS
POSTOP
9-15 
MONTHS
POSTOP
PREOP
30
G
l
o
b
a
l
 
q
u
a
l
i
t
y
 
o
f
 
l
i
f
e
r
a
t
i
n
g
PREOP 2-6 
MONTHS
POSTOP
9-15 
MONTHS
POSTOP
G
l
o
b
a
l
 
q
u
a
l
i
t
y
 
o
f
 
l
i
f
e
r
a
t
i
n
g
 
(
c
a
r
e
g
i
v
e
r
)
%
 
c
h
a
n
g
e
 
g
l
o
b
a
l
 
q
u
a
l
i
t
y
 
o
f
 
l
i
f
e
r
a
t
i
n
g
 
(
c
a
r
e
g
i
v
e
r
)
Global quality of life
8
6
4
2
0
10
8
6
4
2
0
Patients
Caregivers
*P<.05
**P<.01
***P<.001
200
150
100
50
0
200
150
100
50
0
1200
1000
800
600
400
200
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
Patient no.
Patient no.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
Patient no.
patient no.
A B C
DE F
GH I
Figure 1 Bar charts (A–C) and line plots (D–I) of outcomes for BFMDRS-M (A, D and G), BFMDRS-D (B, E and H) and global quality of
life ratings (C, F and I). Means  2 SEM are shown in the bar charts. The line plots show individual values per patient plotted for each time
point, the middle panel showing original data, the lower panel depicting percentage change at 2–6 and 9–15 months with preoperative
values set to 100% to make improvements and deteriorations easier to distinguish. Signiﬁcance levels are given on the right. Parentheses
signify that the result is not signiﬁcant any longer after Bonferroni correction.
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The surgical target in all patients included in this study was the
bilateral GPi. Out of 22 patients in whom information was avail-
able on anaesthesia, 3 were implanted under local anaesthesia,
while the remaining patients were implanted under general anaes-
thesia. Information about the target coordinates was available in
12 of 23 patients. However, different localization techniques and
coordinate systems were used across centres, and the information
available regarding target localization techniques was insufﬁcient
to calculate a standard mean target coordinate. For those patients
in whom information on target was available, target coordinates
are listed in Supplementary Table S1.
Stimulation parameters
Mean and standard deviation of pulse frequency, pulse width and
voltage after 2–6 and 9–15 months of continuous DBS are listed in
Table 4. Due to small numbers of patients and different stimula-
tion settings used in different countries, we found no pattern of
stimulation parameters that proved particularly efﬁcient in the
treatment of NBIA-dystonia. However, stimulus duration tended
to be longer at 9–15 months (P=0.069). Patients with longer
Severity of dystonia,
2-6 months
Severity of dystonia,
9-15 months
Improvement >20%
Improvement <20%
Deterioration
Improvement >20%
Improvement <20%
Deterioration
Improvement >20%
Improvement <20%
Deterioration
Improvement >20%
Improvement <20%
Deterioration
Improvement >20%
Improvement <20%
Deterioration
Improvement >20%
Improvement <20%
Deterioration
Severity of disability, 
2-6 months
Severity of disability, 
9-15 months
Quality of life,
2-6 months
Quality of life,
9-15 months
Figure 2 Pie charts of relative improvements in (A) severity of dystonia (BFMDRS-M), (B) severity of disability (BFMDRS-D), and (C)
global quality of life ratings rated by caregivers. The upper panel shows change at 2–6 months, the lower panel shows change at 9–15
months.
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Figure 3 Scatterplots of (A) severity of dystonia preoperatively against change in severity of dystonia at 2–6 months (linear regression,
corr.r
2=0.31, F=9.4, P50.01); (B) combined score for disease duration and severity of dystonia preoperatively (obtained using a
principal component analysis) against change in dystonia at 2–6 months (linear regression, corr. r
2=0.41, F=14.1, P50.001); and
(C) change in severity of dystonia at 2–6 months versus change in disability at 2–6 months (linear regression, corr. r
2=0.40, F=13.2,
P50.005).
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outcome than the rest of the group.
Accompanying pharmacotherapy
Data on anti-dystonic pharmacotherapy were available for
22 patients at 2–6 months and for 18 patients at 9–15 months
after surgery. All patients took at least one antidystonic medica-
tion; the maximum number of drugs was three. After 2–6 months
of continuous neurostimulation, medication was reduced in nine
patients (41%), while in 9 other patients (41%), pharmacological
treatment remained unchanged. In four of the patients (18%), the
dose of pharmacotherapy was increased. After 9–15 months of
continuous GPi-DBS, nine patients (50%) had reduced
anti-dystonic medication, whereas ﬁve patients (28%) were on
the same medication and four patients (22%) were taking
increased medication compared with their preoperative medication
regimen.
Adverse events
Information on adverse events and side effects was available for
22 out of 23 patients. Adverse event information was reviewed by
two neurologists (A.P. and L.T.) and classiﬁed according to the
following criteria: (i) adverse events that occurred within
30 days after the surgical intervention and could be related to
surgery were regarded as surgical; (ii) adverse events that were
reversible by modifying the stimulation parameters were regarded
as stimulation-related; (iii) adverse events that related to the tech-
nical integrity of the implanted stimulation system were classiﬁed
as device-related; and (iv) all other adverse events which could
either arise from the disease or its progression or other comorbid-
ities were classiﬁed as patient-related. A summary of adverse
events is given in Table 5.
Surgical adverse events
Patient 2 had a wound-healing problem in the abdomen at the
site of pulse generator implantation. The day after DBS surgery,
Patient 10 sustained a dystonic storm leading to a spontaneous
open fracture of the left femoral bone. The initial worsening of
symptoms resolved after several days of stimulation and he sub-
sequently experienced marked beneﬁt in severity of dystonia.
Stimulation-related adverse events
Patient 1 suffered from blepharospasm under monopolar stimula-
tion, which resolved under bipolar stimulation. Patient 9 displayed
mild worsening of gait and balance after initial programming
which resolved after adjustment of stimulation parameters.
Patient 10 complained about phosphenes and paraesthesia due
to neurostimulation, which subsided with prolonged stimulation
and gradual adjustment of the stimulation parameters. Patient
11 reported hyperkinetic movements of neck and trunk when
voltage of stimulation was increased too quickly. Patient 22 suf-
fered from worsening of pre-existing gait freezing under high
amplitude stimulation of more caudal electrode contacts.
Device-related adverse events
Patient 20 experienced paraesthesias in the area around the gen-
erator implant which were found to be due to leakage of electric-
ity. Patient 3 suffered from a dislocation of the pulse generator
and cables that required surgical correction 22 months after the
initial implantation, at a time point that was outside of the obser-
vation period of this study. Out of 19 patients in whom this
Table 5 Serious adverse events and stimulation-related
adverse events reported by patients and centres
Event SAE AE
Surgical adverse events
Wound healing disorder x
Fracture of femur due to dystonic exacerbation
one day after implantation
x
Patient-related adverse events
Pneumonia two years after implantation
resulting in death
a
x
Dystonic storm (onset prior to DBS) resulting in death x
Subluxation of hip with necrosis of head of femur
and chondrolysis necessitating hospitalization
x
Viral infection with hospitalization x
Fall with consecutive worsening of symptoms
and hospitalization
x
Stimulation-related adverse events
Visual disturbance (reversible) x
Mild hyperkinesia (reversible) x
Paraesthesias (reversible) x
Worsening of gait and balance (reversible) x
Worsening of gait freezing (reversible) x
Blepharospasm under monopolar stimulation x
Device-related adverse events
Paraesthesias in the area of the generator implant x
Dislocation of pulse generator and cables
necessitating surgical revision
a
x
a: These events occurred outside the formal period of observation (preoperative to
15 months postoperatively).
Table 4 Mean stimulation parameters at 2–6 and 9–15 months postoperatively
2–6 months after DBS (n=19); mean (range) 9–15 months after DBS (n=13); mean (range)
Parameter Left Right Left Right
Pulse frequency (Hz) 133.7 (60–215) 133.7 (60–215) 128.5 (60–185) 128.5 (60–185)
Pulse width (ms) 194.2 (60–450) 197.4 (60–450) 244.6 (60–450) 244.6 (60–450)
Pulse amplitude (V) 2.83 (1.0–5.0) 2.78 (1.0–5.0) 2.73 (1.3–4.6) 2.76 (1.3–4.6)
Data are presented as (meanSD).
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due to exhaustion during the 15 months observation period.
Patient-related adverse events
Two years after DBS implantation (and thus outside of the formal
observation period), Patient 4 developed aspiration pneumonia
with lethal outcome. Patient 8 was scheduled for elective DBS
but suffered a dystonic crisis with respiratory insufﬁciency.
Regrettably, emergency GPi-DBS in combination with intrathecal
baclofen did not improve his clinical situation and he died of a
dystonic crisis six weeks after surgery. Patient 1 suffered a severe
systemic viral infection seven months after electrode implantation
with hospitalization and subsequent decline of motor control and
speech. Patient 3 suffered a subluxation of the left hip. An osteot-
omy procedure was conducted nine months after DBS surgery
with subsequent complications (necrosis of the head of the
femur and chondrolysis), which considerably limited his mobility
and quality of life. Patient 13 suffered a serious fall six months
after GPi-DBS followed by a continuous deterioration of his
condition.
Discussion
These results indicate that bilateral GPi-DBS is effective in improv-
ing the severity of dystonia in both the short (2–6 months) and
long-term (9–15 months). The mean improvement in severity
of dystonia at 9–15 months was 25.7%. Compared with preop-
erative status for the whole group, quality of life also showed
an improvement, whereas disability did not improve signiﬁcantly.
At 9–15 months postoperatively, 66.7% of patients showed
an improvement in severity of dystonia of 20% or more, and
31.3% showed an improvement in disability of 20% or more.
Global quality of life ratings showed a median improvement
of 83.3% at 9–15 months, 64.7% of patients improved
by 20% or more. Severity of dystonia preoperatively and dis-
ease duration predicted improvement in severity of dystonia at
2–6 months. Improvement in disability at 2–6 months, as well as
at 9–15 months, correlated with improvement in severity of dys-
tonia. However, none of the preoperative scores were success-
ful in predicting improvement in disability and quality of life.
Pharmacotherapy was reduced in 50% of patients 9–15 months
after GPi-DBS.
Although these ﬁndings are positive and encouraging, our study
has several limitations. Due to the retrospective and multi-centre
nature of this study, some data were missing. By working in par-
allel through movement disorders centres, surgical centres and
patient support groups we tried to identify as many patients
with NBIA implanted with DBS as possible. However, patients
who were not organized within the support groups, or underwent
surgery at centres not able or willing to participate, may have
escaped our survey. A further problem was that due to the wide
variability of the NBIA phenotype, clinical scales do not always
entirely suit all individuals. In addition, retrospectively obtained
caregiver quality of life ratings are subject to bias, as all subjects
received GPi-DBS. Furthermore, retrospective assessment of
quality of life will exaggerate the effect of therapy due to recall
bias. Despite these limitations, we believe that our study shows a
realistic picture of the outcome of GPi-DBS in dystonia in NBIA
patients. In particular, these results are important because all
cases, including those with non-favourable outcomes, were
included. This study had no formal monitoring, but was carried
out through careful retrospective evaluation of patient records.
Thus, under-reporting of adverse events is possible.
In our patient sample, we were not able to assess the efﬁciency
of GPi-DBS in different genetic subtypes of NBIA because all
patients in whom genetic testing had been performed had pan-
tothenate kinase-associated neurodegeneration except for one, in
whom no mutation was identiﬁed. Thus, a statistical comparison
between pantothenate kinase-associated and non-pantothenate
kinase-associated neurodegeneration was not possible. However,
we predict that severity of dystonia, as well as presence or
absence of other symptoms, are more powerful predictors of ther-
apeutic outcome than genetic status.
There was a discrepancy in the current survey between the
motor outcome of GPi-DBS and the comparatively small effect
on disability as assessed using the BFMDRS disability scale.
There are several reasons why this might have been the case.
The current study was not blinded, causing a potential observer
bias by the clinical rater assessing the dystonia. Furthermore, the
BFMDRS disability scale was developed for use in patients with
primary torsion dystonia and may not be well suited for some of
the patients in this cohort, who can be paediatric and severely
disabled. For example, the BFMDRS only distinguishes between
‘walking with help’ and ‘wheelchair-bound’. The ability to control
the wheelchair independently, or the autonomous transfer in and
out of it, is not taken into account. Speciﬁc scales for patients with
NBIA are unavailable. A scale used in paediatric settings is the
Care and Comfort Hypertonicity Questionnaire (Nemer McCoy
et al., 2006), which was developed for use in children with cere-
bral palsy. Since DBS in paediatric patients is still relatively uncom-
mon, patients are frequently attended by adult neurologists, who
more frequently use the BFMDRS and are often unfamiliar with
paediatric scales. Thus, the BFMDRS as the most frequently
employed scale is valuable because it allows comparison with
other studies, although it might not adequately reﬂect changes
at all levels of severity.
Likewise, there was a discrepancy between the small effect on
disability and the rather impressive improvement in quality of life.
Of course, retrospective quality of life ratings may have overesti-
mated the effect of therapy due to a recall bias. However, quality
of life in dystonia also reﬂects numerous factors beyond disability,
such as pain due to dystonia, stigma, fatigue due to medication
and several other factors (Mueller et al., 2008), all of which are
not addressed in the BFMDRS-D. Although not quantiﬁed in the
current survey, pain was reported to be reduced in many of the
patients in the cohort, as was social stigma due to very visible
dystonia. Thus, it is conceivable that quality of life improved con-
siderably despite relatively small changes in disability.
The study by Castelnau and colleagues (2005) reported a
74.6% improvement in severity of dystonia, compared with
25.7% in the current study, as well as a 53% improvement in
disability compared with 15.8% improvement in the current study.
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disease duration, age at surgery, severity of dystonia or severity
of disability. The cases reported by Castelnau et al. (2005) were
stimulated with very long impulse durations which differ from
those used in the current study. Furthermore, Castelnau and col-
leagues (2005) have considerable experience with DBS in second-
ary childhood dystonia, and thus, may have selected suitable
patients more carefully than other centres. Also, postoperative
programming may have been carried out based on more expertise.
The strength of the current study is that patients were included
regardless of outcome, thus giving a realistic picture of the out-
comes of GPi-DBS in NBIA. In particular, no lethal outcomes were
reported in the Castelnau et al. (2005) study. In our sample, one
patient died during the period of observation due to dystonic
storm with onset before the operation. A second patient died of
pneumonia two years after surgery. No systematic quantiﬁcation
of any accompanying symptoms, such as those due to pyramidal
tract degeneration, was done in either the Castelnau et al. (2005)
study or our study. Thus, the difference in outcome may be
related to differences in neurological signs and symptoms, other
than dystonia itself, between the two population samples. This
may be due to differences in (not explicitly stated) selection crite-
ria between different centres.
We found no signiﬁcant difference in severity of dystonia, dis-
ability and quality of life between 2–6 months and 9–15 months
after surgery. Castelneau and colleagues (2005) also report a
sustained response over a maximum of 42 months. Although
there was no signiﬁcant difference between 2–6 months and
9–15 months outcomes, the data in Fig. 1 suggest a relative out-
come decline at least in some patients. We think this decline is due
to disease progression. In cases where MRI imaging has been
repeatedly performed, there is an increase in the area of T2
hypointensity in the putamen and globus pallidus which is paral-
leled by clinical deterioration (Hayﬂick et al., 2006). Of course,
there is always the possibility of a placebo effect or an observer
bias component, which cannot be ruled out in an open trial.
However, the placebo effect of GPi-DBS in dystonia seems to be
relatively small (Kupsch et al., 2006). Recurrence of dystonia
during temporary reductions in amplitude, or while turning off
the stimulation to change settings, suggest a maintained stimula-
tion effect throughout. Neither this study nor the Castelneau et al.
(2005) study had a control group of patients with NBIA who did
not undergo GPi-DBS. However, a randomization of NBIA patients
deemed suitable for DBS into a GPi-DBS group and a non-GPi-
DBS group is difﬁcult to justify ethically. An open control group of
patients who choose not to undergo GPi-DBS may serve as a
viable compromise control group for further studies.
Since this was a retrospective study, factors other than GPi-DBS
to treat dystonia, e.g. pharmacotherapy, were reported but not
controlled. However, out of 22 patients for whom information on
pharmacotherapy was available, 18 (82%) either had reduced
medication, or their pharmacotherapy was unaltered at three
months. Thus, the antidystonic effect can be safely attributed to
GPi-DBS and is unlikely to be due to changes in pharmacotherapy.
Although the reduction in medication is mostly dictated by the
treating physician, it may be relevant because antidystonic drugs
frequently cause side effects such as drowsiness. A reduction in
medication will reduce side effects, thereby possibly improving
quality of life.
We found in patients with NBIA that more severe dystonia
preoperatively predicts greater improvement postoperatively. In
contrast, in primary generalized dystonia subjects, Vasques and
colleagues (2009) found that higher preoperative BFMDRS
scores were associated with less improvement in primary general-
ized dystonia postoperatively. In addition, longer disease duration
and the presence of ﬁxed, skeletal deformities in those with pri-
mary generalized dystonia has been shown to be associated with
less favourable outcome after treatment with GPi-DBS (Isaias
et al., 2008; Vasques et al., 2009). These differences in our ﬁnd-
ings may be related to the course of dystonia in patients with
NBIA as compared to patients with primary generalized dystonia.
In NBIA, dystonia can develop relatively rapidly, resulting in severe
generalized dystonia without ﬁxed skeletal deformities. Therefore,
the issue of disease duration and the presence of ﬁxed skeletal
deformities may not be relevant to the NBIA patient. Hence, the
signiﬁcant improvement observed in severely affected NBIA
patients encourages the consideration of GPi-DBS as a viable
treatment in those with severe dystonia and underlying NBIA
since skeletal deformities are less likely in these patients.
There were no systematic differences in terms of stimulation
settings between patients with good and bad outcome. Given
the sample size, the heterogeneity of the clinical picture and the
number of other factors likely contributing to outcome, this is not
surprising. Other studies of dystonia with larger, more homoge-
neous patient samples have also not found any particular settings
which are more effective than others (Vasques et al., 2009).
In summary, we present evidence that secondary dystonia in
NBIA improves with bilateral GPi-DBS. However, this improvement
does not seem to be equal to the beneﬁt reported in patients with
primary generalized or tardive dystonias (Trottenberg et al., 2005;
Vidailhet et al., 2005; Kupsch et al., 2006). NBIA patients with
more severe dystonia seem to derive greater beneﬁt from
GPi-DBS. We recommend operating on patients as soon as dysto-
nia becomes disabling and before any possible secondary skeletal
deformities arise. A multi-centre, well-controlled prospective study
is necessary to get large numbers of cases of this heterogeneous
condition and thus be able to better predict the outcome from
surgery. For this purpose, we are maintaining a prospective data-
base of patients with NBIA undergoing DBS. We encourage the
DBS community to contribute patients to this database with the
aim of collecting systematic evidence of treatment effects in
this rare condition.
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Univ. of California at San Francisco, San Francisco, CA, USA;
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